Abstract
Thalidomide, an angiogenesis inhibitor is currently used in clinical trials in the US and Europe in combination with chemotherapy for the treatment of various solid tumors. The prognosis of patients suffering from small-cell lung cancer (SCLC) is poor. A 73-year-old female with extensive disease of SCLC was given six courses of chemotherapy with adriamycine, cyclophasphamide and oncovine, which led to complete remission of the disease. Following written informed consent, the patient has been treated with thalidomide 200 mg orally on a daily basis for 2 years and 5 months. There has been no sign of tumor recurrence during the follow-up. This case underlines the possible role of additional treatment with angiogenesis inhibitors in combination with traditional chemotherapy in the therapy of SCLC. Although there is no proof that thalidomide contributed to this good outcome and no conclusions can be drawn from this treatment in a single patient, further studies may determine the role of thalidomide as an adjuvant antiangiogenic agent in the therapy of SCLC.
This is a preview of subscription content, log in via an institution to check access.
References
Stephens TD, Bunde CJW, Fillmore BJ. Mechanism ofaction in thalidomide teratogenesis. Biochem Pharm 2000; 12: 1489–99.
Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: Systematic review of the literature and ofunpublish ed observations. J Inflamm 1996; 46: 177–211.
Ching LM, Xu ZF, Gummer BH, Palmer BD et al. Effect of thalidomide on tumour necrosis factor production and anti-tumor activity induced by 5,6–dimethylxanthenone-4 acetic acid. Br J Cancer 1995; 72: 339–43.
Schneider J, Wnendt S, Korioth J, Zwingenberger K. Thalidomide inhibits super-antigen-induced TNF? release in mice. 12th European Immunology Meeting of the European Federation of Immunologic Societies, Barcelona, Spain, June 14–17, 1994.
Kelly K. New chemotherapeutic agents for small cell lung cancer. Chest 2000; 117(Suppl. 4): 156S-62S.
Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, vincristin versus cisplatin etoposide versus alternation of these regimens in small cell lung cancer: A phase III trial of the Southeastern cancer study group. J Clin Oncol 1992; 10: 282–91.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353–64 (Review).
Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341(21): 1565–71.
Fine HA. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy and gene therapy. Neur Clin 1995; 13: 827–46.
Minchington AI, Fryer KH, Wendt KR et al. The effect of thalidomide on experimental tumor and metastases. Anticancer Drugs 1996; 7: 339–43.
Figg WD, Bergan R, Brawley O et al. Randomized phase II study of thalidomid e in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 1997; 16: 333a.
Long G, Vredenburgh J, Rizzeri DA et al. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 79(2): 181a.
D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082–85.
Salven P, Ruotsolainen T, Mattson K, Joensuu H. High pretreatment serum levels of vascular endothelial growth factor (VEGF) is associated with poor outcome in small cell lung cancer. Int J Cancer 1998; 17, 79(2): 144–6.
Takigawa N, Segawa Y, Fujimoto N et al. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res (Mar-Apr), 1998; 18(2B): 1251–4.
Matsuyama W, Hashiguchi T, Mizoguchi A et al. Serum levels of Vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118(4): 948–51.
Fishman JS, Feins NR, D'Amato RJ, Folkman J. Long term remission of Crohn's disease treated with thalidomide: A seminal case report. Angiogenesis 1999; 3: 201–4.
Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445–6 (Letter).
Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 2001; 34(Suppl 4): 3–7.
Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2001; 34(Suppl 3): 81–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mall, J., Philipp, A., Mall, W. et al. Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy. Angiogenesis 5, 11–13 (2002). https://doi.org/10.1023/A:1021546630577
Issue Date:
DOI: https://doi.org/10.1023/A:1021546630577